Home › Funds › Bellevue Group AG › CRNX

Bellevue Group AG position in CRNX

CRINETICS PHARMACEUTICALS IN

Bellevue Group AG reported holding 2,620,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$98.0M, representing 2.06% of its reported portfolio and ranking #16 among its reported holdings. Bellevue Group AG has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)2.62M sh
Reported value held$98.04M
Portfolio Weight2.06%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's CRNX position evolved

Bellevue Group AG first disclosed a stake in CRNX in Q4 2025 at 4,040 shares (US$188K). The position peaked in Q1 2026 at 3,280,000 shares, worth US$119.1M. Across 3 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,620,000 shares valued at US$98.0M — a reduction of -660,000 shares quarter over quarter.. Notable position changes include a 81088% increase in Q1 2026.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 4.04K $188.06K New
Q1 2026 3.28M $119.13M Add
Q2 2026 2.62M $98.04M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has Bellevue Group AG held CRNX?

Bellevue Group AG has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Bellevue Group AG's current position in CRNX?

As of Q2 2026, Bellevue Group AG holds 2.62M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $98.04M, representing 2.06% of its reported portfolio and ranking #16.

Has Bellevue Group AG been buying or selling CRNX?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in CRNX. The position peaked in Q1 2026 at 3.28M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.